Sai-Hong Ignatius Ou

Case Background The United States Securities and Exchange Commission (SEC) has filed a complaint against Sai-Hong Ignatius Ou, alleging that he engaged in insider trading by using confidential information to purchase Nuvalent stock before its positive drug trial data was publicly disclosed. Key Allegations Ou, a medical doctor and principal investigator for Nuvalent's NVL-520 clinical trials, received material nonpublic information about the trial's progress and purchased 80,000 shares of Nuvalent stock. He then sold these shares after the public disclosure of positive results, profiting $1,520,455.37. Compliance Considerations The SEC seeks an injunction against future violations, disgorgement of ill-gotten gains, civil penalties, and an officer-and-director bar. This case highlights the importance of maintaining confidentiality and avoiding insider trading in the securities industry.